During the pandemic, oncology research teams around the world embraced decentralized clinical trials (DCTs) to keep patients and investigators safe. But in the purest sense, a “siteless” decentralized trial may not be suited to the majority of cancer patients receiving investigational therapies. The solution is a hyhbrid DCT model, which can reduce logistical burdens that disproportionately affect diverse and/or economically disadvantaged communities. Download the paper to learn the advantages of hybrid DCTs in oncology from the patient’s viewpoint, the regulatory and technology shifts that favor these strategies and the social/cultural contexts that will affect such trials going forward.
Download the article below
